21:27 , Jun 27, 2019 |  BC Extra  |  Company News

Conserving cash, ImmunoGen to pursue narrower indication for bruised mirvetuximab

Immunogen is gutting its workforce and shelving at least two early stage programs to focus on the asset that put the biotech in this precarious position in the first place, antibody-drug conjugate mirvetuximab soravtansine. ImmunoGen...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
19:19 , May 15, 2019 |  BC Extra  |  Company News

ImmunoGen looks to next Phase III after FDA rebuffs accelerated approval path for mirvetuximab

ImmunoGen plans to start a second Phase III trial before year end of mirvetuximab soravtansine that will focus on ovarian cancer patients with high FOLR1 expression after FDA told the company that data from a...
17:28 , Mar 8, 2019 |  BC Week In Review  |  Clinical News

ImmunoGen down on Phase III ovarian cancer miss

ImmunoGen lost $2.21 (47%) to $2.51 on March 1 after reporting that mirvetuximab soravtansine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III FORWARD I trial to treat FOLR1-positive, platinum-resistant ovarian...
20:29 , Mar 1, 2019 |  BC Extra  |  Clinical News

ImmunoGen down on Phase III ovarian cancer miss

ImmunoGen Inc. (NASDAQ:IMGN) lost $2.21 (47%) to $2.51 on Friday after reporting that mirvetuximab soravtansine missed the primary endpoint of improving progression-free survival (PFS) in the Phase III FORWARD I trial to treat FOLR1-positive, platinum-resistant...
03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
21:43 , Jan 18, 2019 |  BioCentury  |  Product Development

ImmunoGen’s milestone year

Nearly three years after refocusing the company to boost long-term value creation, ImmunoGen Inc. expects 2019 to be the year the changes will begin to bear fruit, starting with Phase III data from its lead...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest combinations of bispecific small molecules targeting fluorescein and CAIX, PSMA or FOLR1 plus anti-fluorescein CAR T cells could help treat triple-negative breast cancer (TNBC). The bispecific adapter molecules consist...
18:46 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Sutro proposes $75M IPO

Sutro Biopharma Inc. (South San Francisco, Calif.) proposed on Aug. 29 to raise $75 million in an IPO on NASDAQ underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow. Concurrent with the proposed IPO,...
22:51 , Aug 29, 2018 |  BC Extra  |  Financial News

Sutro proposes $75M IPO

Sutro Biopharma Inc. (South San Francisco, Calif.) proposed on Wednesday to raise $75 million in an IPO on NASDAQ underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow. Concurrent with the proposed IPO, Merck...